؊6 M AM failed to stimulate cAMP production. In mRAMP2/mCLR-(14 -20A) expressing cells the cAMP response to AM was minimally restored, and the EC 50 was >100 nM. In conclusion, the deletion of the amino acid sequence TRNKIMT of the extreme N terminus of the mCLR maintained CGRP receptor function of mRAMP1/receptor heterodimers, but AM no longer activated the mutant mCLR-(⌬14 -20) in the presence of mRAMP2. The TRNKIMT sequence is required for normal mCLR/mRAMP2 association, and as a consequence, high affinity AM binding signaling the activation of adenylyl cyclase.
The neuropeptides ␣-and ␤-calcitonin (CT) 1 gene-related peptide (CGRP) (1-37) and the multifunctional peptide hormone adrenomedullin (AM) of 52 amino acids in man and 50 amino acids in the rat are potent vasodilators (1) . CGRP and AM are only 20% identical but have in common ring structures of six amino acids linked by disulfide bonds between cysteine residues and amidated C termini, both required for biological activity.
Molecularly defined receptors for CGRP and AM are CT-like receptor (CLR)/receptor-activity-modifying protein (RAMP) 1 and CLR/RAMP2 heterodimers, predominantly linked to cAMP production (2) . The CLR belongs to the family B of G proteincoupled receptors with seven transmembrane domains that includes the 60% homologous CT receptor and receptors for secretin and parathyroid hormone (PTH). The CLR, unlike the other known members of this receptor family, requires as associated proteins the RAMP for the functional expression. RAMP1 and RAMP2 and a third, RAMP3, consist of between 147 and 189 amino acids. They are single transmembrane domain proteins with 30% amino acid sequence similarity. Their N-terminal extracellular domains of between 90 and 110 amino acids define in part CGRP and AM selectivity of the CLR (3) . Substitution of the 18 N-terminal amino acids of the human CLR by the corresponding domain of the porcine CT receptor revealed a fully functional CGRP receptor in the presence of human RAMP1, but the RAMP2-dependent AM receptor function was impaired (4) . This implies that subdomains of both the CLR and the RAMP determine distinct binding interaction sites for CGRP and AM in the corresponding heterodimers.
In other receptors of the B family of G protein-coupled receptors critical determinants for high affinity ligand binding are localized near the N terminus. Photochemical cross-linking of PTH analogs and site directed mutagenesis identified Thr 33 and Glu 37 in the N-terminal extracellular domain of the rat PTH receptor as determinants for PTH binding (5) . Similarly, 125 I-CT analogs with photoreactive p-benzoyl-L-phenylamine in positions 16 and 26 labeled Thr 30 close to the N terminus and Phe 137 adjacent to the first transmembrane domain of the human CT receptor (6) . Similarly, in the secretin receptor amino acids 1-10 were indispensable for high affinity ligand binding (7) .
Here, amino acids 14 -20 of the mouse CLR with the sequence TRNKIMT were identified as a critical determinant for the functional interaction of the mCLR/mRAMP2 with AM. Importantly, the deletion of the TRNKIMT sequence in the mCLR maintained the CGRP receptor function in the presence of mRAMP1. Substitution of amino acids 14 -20 by alanine revealed a low affinity mCLR/mRAMP2 AM receptor.
EXPERIMENTAL PROCEDURES
Materials-Cell culture products were supplied by Invitrogen. Rat ␣CGRP (CGRP) and rat AM (AM) were obtained from Bachem AG (Bubendorf, Switzerland). Chemicals and other reagents were purchased from Sigma and VWR International GmbH (Darmstadt, Germany).
Construction of mCLR Mutants-A DNA fragment encoding amino acids 1-292 of the mCLR was subcloned into the pBluescript SKϪ vector (Stratagene, La Jolla, CA). The amino acid deletions and substi-* This work was supported by the Swiss National Science Foundation, the University of Zurich, and the Schweizerischer Verein Balgrist. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: Klinik Balgrist, Research Laboratory for Calcium Metabolism, Forchstrasse 340, 8008 Zurich, Switzerland. Tel.: 41-1-3861665; Fax: 41-1-3861652; E-mail: wborn@balgrist.unizh.ch. 1 The abbreviations used are: CT, calcitonin; CGRP, CT gene-related peptide; AM, adrenomedullin; CLR, CT-like receptor; RAMP, receptoractivity-modifying protein; PTH, parathyroid hormone; BS3, bis(sulfosuccinimidyl) suberate; h, human; m, mouse; r, rat. tutions in the extreme N-terminal region of the mCLR illustrated in Fig. 1 were introduced into the corresponding DNA sequence with the protocols of the QuikChange® Multisite-Directed Mutagenesis Kit (Stratagene). The primers carrying the mutations were designed according to the recommendations given by Stratagene. PCR was carried out in a final volume of 50 l, containing 100 ng of plasmid template, 50 pmol of 5Ј and 3Ј primers, and 2.5 units of the PfuUltra TM High-Fidelity DNA Polymerase (Stratagene). The annealing temperature was set to 55°C for the first 5 cycles and to 62°C for the additional 25 cycles. The plasmid template was digested with DpnI, and the PCR products were transformed into calcium competent Escherichia coli XL-1 Blue cells. The DNA fragments encoding the N-terminal mCLR subregion with the introduced mutations were sequenced in both directions with ABI PRISM TM DNA Analizer (Applied Biosystems, Foster City, CA). DNA fragments carrying the desired mutations were excised from pBluescript SKϪ and cloned into a pcDNA 3.1 construct that provided an in frame DNA fragment encoding the non-modified C-terminal region of the mCLR.
Cell Culture and Transfection-COS-7 cells were cultured in Ham's F-12/Dulbecco's modified Eagle's medium (4.5 g/liter glucose) medium (1:1) supplemented with 10% fetal calf serum and 2 mM glutamine (cell culture medium). For transfection the cells were seeded in 24-or 6-well plates or in 100-mm culture dishes at a density of 15,000 cells/cm 2 . 48 h later the cells were transfected with the indicated receptor and RAMP expression constructs and linear polyethylenimine (25 kDa) (Polysciences, Warrington, PA). Briefly, 0.2 g/cm 2 plasmid DNA was diluted with 6.25 l/cm 2 cell culture medium. 0.5 g/cm 2 polyethylenimine in 6.25 l/cm 2 cell culture medium was prepared separately. The solutions were then combined and vortexed immediately. After incubation for 15 min at room temperature, the volume was adjusted to 125 l/cm 2 with cell culture medium and the solution added to the cells. The cells were incubated at 37°C overnight. The volume was then increased to 250 l/cm 2 with cell culture medium and the cells incubated for 2 days. Stimulation of cAMP Production-2 days after transfection the COS-7 cells were incubated at 37°C for 15 min with the indicated concentrations of rCGRP and rAM in cell culture medium without fetal calf serum but supplemented with 1 mM isobutylmethylxanthine and 0.1% bovine serum albumin. Subsequently, cAMP was extracted from the cells and measured by radioimmunoassay as described previously (8) .
Immunofluorescent Staining of Intact and Mutant V5-mCLR and of myc-mRAMP1 and myc-mRAMP2 at the Surface of COS-7 Cells-
The cells were grown and transfected on coverslides in 24-well plates. V5 and myc immunofluorescence staining was carried out 2 days after transfection. The cells were fixed with 4% formalin in phosphate-buffered saline for 20 min at room temperature, washed with phosphatebuffered saline, and preincubated with Ham's F-12/Dulbecco's modified Eagle's medium containing 0.1% bovine serum albumin for 30 min at room temperature. The cells were then incubated for 2 h at room temperature in the same medium with mouse monoclonal antibodies to V5 (Invitrogen) and/or rabbit polyclonal antibodies to myc (Abcam, Cambridge, UK) (diluted 1:400). Subsequently the cells were stained for 30 min in the dark with Alexa488 goat anti-rabbit serum (Molecular Probes, Eugene, OR) and/or Cy3-conjugated sheep anti-mouse serum (Sigma) (diluted 1:200). After mounting of the coverslips with ImmuMount (Thermo Shandon, Inc., Pittsburgh, PA) the fluorescence was detected by a Kappa DX20 CCD camera connected to an Eclipse E600 Nikon microscope with a 0.45ϫ projection lens through a Plan Fluor 20ϫ/0.5 DLL objective using B-2A and G-2A filter blocks.
Protein Cross-linking, Immunoprecipitation, and DeglycosylationCell surface protein cross-linking was carried out with 10 mM bis(sulfosuccinimidyl) suberate (BS3; Pierce). The cells were lysed with 50 mM Hepes, pH 7.5, 7 mM MgCl 2 , 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 3 g/ml aprotinin, 3 g/ml leupeptin, 1 mg/ml dodecyl-␤-Dmaltoside, and 0.2 mg/ml cholesterolhemisuccinate (cell lysis buffer). V5-tagged receptors were immunoprecipitated from the cleared lysates at 4°C by sequential incubation with 50 l of ImmunoPure® Immobilized Protein G (Pierce) for 1 h, 3 l of V5 antibodies for 2 h, and 50 l of ImmunoPure® Immobilized Protein G overnight on an end-over-end rotator. The immobilized proteins were washed twice with cell lysis buffer and then deglycosylated in 45 l of 10 mM Tris-HCl, pH 7.5, 10 mM EDTA, 0.1% SDS, 0.5% octylglucopyranoside, 1% ␤-mercaptoethanol supplemented with 2 units of N-glycosidase F (F. Hoffmann-La Roche, Ltd., Basel, Switzerland) at 37°C for 18 h. Proteins bound to ImmunoPure® Immobilized Protein G were eluted twice with 15 l SDS-PAGE sample buffer, and the eluates were pooled. Proteins in 50 l of total cell extracts were deglycosylated with 2 units of N-glycosidase F at 37°C for 18 h. The reactions were stopped with protein gel loading buffer.
Western Blot Analysis-Proteins in cell extracts obtained with lysis buffer or immunoprecipitated proteins were separated by SDS-PAGE and electrotransferred to nitrocellulose Hybond TM ECL TM membranes (Amersham Biosciences UK Ltd., Buckinghamshire, UK) in a TransBlot® SD semidry transfer cell (Bio-Rad) at 20 V for 80 min. Immunoblots were washed with water for 5 min, 2 M NaOH for 10 min, and with water for 5 min. They were then blocked with 5% low fat milk. The epitope-tagged proteins were detected with alkaline phosphatase-labeled monoclonal V5 and myc antibodies (Invitrogen) (diluted 1:3,000 and 1:15,000 in 1% low fat milk, respectively) or with mouse monoclonal myc antibodies 9E10.2 (diluted 1:50 in 5% low fat milk) (9) and secondary alkaline phosphatase-conjugated goat antibodies to mouse IgG (1: 15,000 final dilution in 1% low fat milk) (The Jackson Laboratory, Bar Harbor, ME). Actin as a reference for total protein loading was visualized with monoclonal antibodies to actin (diluted 1:5,000 in 5% low fat milk) (Chemicon International, Temecula, CA) and secondary alkaline phosphatase-labeled goat antibodies to mouse IgG (1:15,000 in 1% low fat milk). The alkaline phosphatase-conjugated antibodies were visualized by chemiluminescence with the Immun-Star® AP substrate pack (Bio-Rad) using a VersaDoc TM Imaging System (Bio-Rad). Data Analysis-The values for half-maximal effective concentrations (EC 50 ) were calculated by non-linear regression analysis using Prism 3.0 (GraphPad Software, Inc., San Diego, CA). The results are means Ϯ S.E. Differences between mean values were analyzed by analysis of variance. p Ͻ 0.05 was considered statistically significant.
RESULTS

Total and Cell Surface Expression of Intact and Mutant
V5-mCLR and of myc-mRAMP1 and myc-mRAMP2-The relative expression levels of the V5-mCLR and of the N-terminal deletion mutants and of myc-mRAMP1 and myc-mRAMP2 in transiently transfected COS-7 cells were estimated on Western blots of cell extracts (Fig. 2) . The expression of the intact V5-mCLR was the same in the absence and presence of myc- 
FIG. 2.
Western blot analysis of total cell extracts. COS-7 cells were grown in 6-well plates and transfected with indicated combinations of myc-mRAMP1 or myc-mRAMP2 and V5-mCLR or V5-mCLR mutant expression constructs. In transfections with the V5-mCLR alone, empty pcDNA3 expression vector was added to keep the DNA concentrations constant. Two days after transfection, the cells were harvested and the proteins were extracted with cell lysis buffer. Extracts were treated with N-glycosidase F and separated on a 10 -20% gradient SDS-polyacrylamide gel. Proteins were blotted on a nitrocellulose membrane, and V5-tagged receptors and myc-tagged RAMP were visualized with alkaline phosphatase-conjugated V5 and myc antibodies. Actin as a reference for protein loading was detected with mouse monoclonal antibodies to actin and secondary alkaline phosphataseconjugated goat antibodies to mouse IgG. Representative experiments were carried out three times.
mRAMP1. The expression levels of the V5-mCLR-(⌬14 -20) and -(⌬18 -20) in the presence of myc-mRAMP1 were comparable and those of V5-mCLR-(14 -20A) and -(⌬14 -17) slightly higher than that of the intact V5-mCLR. Myc-mRAMP1 was expressed at equal levels with intact and mutant V5-mCLR.
The expression levels of the V5-mCLR in the absence and the presence of myc-mRAMP2 were similar and comparable with those of the V5-mCLR-(⌬18 -20) in the presence of mycmRAMP2. The V5-mCLR-(⌬14 -20) and -(⌬14 -17) were expressed at lower and the V5-mCLR-(14 -20A) at higher levels than the intact V5-mCLR in the presence of myc-mRAMP2. Myc-mRAMP2 was lower in the presence of the V5-mCLR-(⌬14 -17) than together with the V5-mCLR or the other mutants.
The expression of the intact and mutant V5-mCLR and of the myc-mRAMP1 and myc-mRAMP2 at the cell surface was visualized by V5 and myc immunofluorescence staining of intact COS-7 cells (Fig. 3) . Cells transfected with the empty pcDNA3 expression vector or with myc-mRAMP1 alone did not stain (Fig. 3A) , but myc-mRAMP1 was recognized in permeabilized COS-7 cells (not shown). Thus, myc-mRAMP1 in the absence of the V5-mCLR was not transported to the cell surface. But the V5-mCLR and myc-mRAMP2 expressed alone were both recognized at the cell surface. The cell surface expression of the intact V5-mCLR and of the mutants in the presence of mycmRAMP1 or myc-mRAMP2 was comparable (Fig. 3B) . Moreover, the expression of myc-mRAMP1 and myc-mRAMP2 at the cell surface was the same in cells co-expressing the intact V5-mCLR or the different mutants. Taken together, the mutations introduced into the N-terminal extracellular domain of the V5-mCLR did not affect the expression of the receptors and the RAMP at the cell surface.
Stimulation of cAMP Production-In COS-7 cells transiently co-transfected with myc-mRAMP1 and V5-mCLR expression constructs basal cAMP concentrations were 1.1 Ϯ 0.2 pmol/ 100,000 cells. The stimulation of cAMP formation by 10 Ϫ6 M CGRP was 48 Ϯ 9-fold (100%) and indistinguishable in cells expressing myc-mRAMP1/V5-mCLR-(⌬14 -17), -(14 -20A), -(⌬14 -20), or -(⌬18 -20) (Fig. 4, Table I ). The EC 50 -mRAMP1 and myc-mRAMP2 . A, COS-7 cells were transfected with pcDNA3 or with V5-mCLR expression construct alone (upper panels) or with myc-mRAMP1 or myc-mRAMP2 expression constructs alone (lower panels). After fixation the cells were incubated with mouse anti-V5 (upper panels) or rabbit anti-myc serum (lower panels) and subsequently stained with Cy3-conjugated sheep anti-mouse serum or with Alexa488-conjugated goat anti-rabbit antibodies, respectively. B, COS-7 cells were transfected with the constructs for the expression of intact V5-mCLR or the indicated mutants together with myc-mRAMP1 (left panels) or myc-mRAMP2 (right panels). The cells were simultaneously incubated with rabbit anti-myc and mouse anti-V5 serum and stained with Alexa488 goat anti-rabbit and Cy3 sheep anti-mouse serum. Photomicrographs were taken for the detection of V5 (red) and myc epitopes (green) from the same field of inspection with identical exposure times using respective filter blocks as described under "Experimental Procedures." Overlays in yellow indicate co-expression of the receptors and the RAMP. Scale bar: 100 m.
values were 0.8 Ϯ 0.2 nM, 9.3 Ϯ 3.4 nM, 59 Ϯ 7.2 nM, and Ͼ100 nM, respectively (Fig. 4, Table I ). In contrast, in myc-mRAMP2/ V5-mCLR-(⌬14 -20)-expressing cells the cAMP levels were not affected at up to 10 Ϫ7 M AM. Taken together, the deletion of amino acids 14 -20 of the extreme N terminus of the mCLR maintains CGRP receptor function in the presence of mRAMP1 but abolishes the mRAMP2-dependent AM receptor activity.
Cell Surface Association of Intact and Mutant V5-mCLR with myc-mRAMP1 and myc-mRAMP2-The association at the cell surface of the V5-mCLR or its mutants with myc-mRAMP1 or myc-mRAMP2 was assessed by chemical cross-linking of corresponding myc-mRAMP/V5-mCLR heterodimers in transiently transfected, intact COS-7 cells. Protein components with a V5 epitope tag were immunoprecipitated from cell homogenates and deglycosylated. The extracted proteins were then separated on SDS-PAGE and analyzed on Western blots with V5 and myc antibodies. Predominant V5-immunoreactive protein components with an apparent size of ϳ50 kDa represented the V5-mCLR and the indicated mutants (Fig. 5) . The amounts of the V5-mCLR and of the mutants in the presence of myc-mRAMP1 were comparable and not different from V5-mCLR in the absence of myc-mRAMP1. In the presence of myc-mRAMP2 the amounts of the V5-mCLR and of the V5-mCLR-(14 -20A) and -(⌬18 -20) were similar, but those of the V5-mCLR-(⌬14 -20) and of the V5-mCLR-(⌬14 -17) were lower. The amount of the V5-mCLR in the absence of myc-mRAMP2 was also lower than in its presence.
The extracts obtained with V5 antibodies from cells that expressed the V5-mCLR or its mutants together with mycmRAMP1 contained myc-immunoreactive protein components of 16 kDa and ϳ66 kDa apparent size. They represented intact myc-mRAMP1 and myc-mRAMP1 cross-linked at the cell surface to the V5-mCLR and the mutants, respectively. This indicated that the deletions and substitutions introduced into the N terminus of the mCLR did not affect the formation and cell surface expression of mCLR/mRAMP1 heterodimers.
Immunoprecipitation with V5 antibodies of cells co-expressing myc-mRAMP2 together with the intact and mutant V5-mCLR revealed predominant myc-immunoreactive protein components of ϳ18 kDa apparent size. They represented deglycosylated myc-mRAMP2 co-precipitating with the intact and mutant V5-mCLR. Interestingly, receptor/myc-mRAMP2 cell surface cross-linking products of ϳ70 kDa were only recognized in extracts of cells that co-expressed myc-mRAMP2 together with the intact V5-mCLR or with the mutant V5-mCLR-(14 -20A) and -(⌬18 -20). All together, this indicated that the deletion of amino acids 14 -17 or 14 -20 of the extreme N terminus of the mCLR did not affect co-immunoprecipitation of mycmRAMP2 but prevented chemical cross-linking at the cell surface. Since the V5-mCLR-(14 -20A) and myc-mRAMP2 revealed a cross-linking product, the Lys 17 residue is excluded as the cross-linking site between the V5-mCLR and myc-mRAMP2. required for the high affinity interaction with AM in the presence of mRAMP2. Deletion of the TRNKIMT sequence abolished the AM receptor function of the V5-mCLR without affecting the expression at the cell surface and heterodimerization with myc-mRAMP2. Chemical cross-linking of myc-mRAMP2 with the V5-mCLR at the surface of intact cells indicates the close proximity of the extracellular domains of the corresponding proteins. Crosslinking was no longer possible when the TRNKIMT sequence of the V5-mCLR was deleted. Cell-surface cross-linking of mycmRAMP2 to the V5-mCLR with a TRNK deletion was also not observed, but here the AM receptor function in the presence of myc-mRAMP2 was maintained. The results may imply that the chemical cross-linker BS3 coupled myc-mRAMP2 to the Lys 17 residue in the V5-mCLR, but this was ruled out by the substitution of the TRNKIMT sequence by 7 alanine residues revealing myc-mRAMP2/V5-mCLR-(14 -20A) cross-linking products indistinguishable from myc-mRAMP2/V5-mCLR. Taken together, the results demonstrate that structural alterations in the N-terminal extracellular domain of the V5-mCLR brought about by the deletion of the TRNKIMT sequence inhibit the formation of a high affinity AM recognition site in mycmRAMP2/V5-mCLR-(⌬14 -20) heterodimers. The structural alterations in the N-terminal extracellular domain of the V5-mCLR are less severe when the TRNKIMT sequence is replaced by 7 alanines. Here, low affinity interaction with AM and chemical cross-linking of the myc-mRAMP2/V5-mCLR-(14 -20A) complex at the cell surface was maintained.
In an attempt to assign the defect in AM receptor function of the V5-mCLR-(⌬14 -20) to parts of the TRNKIMT motif, the TRNK and the IMT sequences were individually deleted. Interestingly, the CGRP and AM receptor functions of the V5-mCLR were minimally affected by the TRNK deletion. The deletion of the IMT sequence, on the other hand, increased the half-maximal concentrations of both CGRP and AM for the stimulation of cAMP formation by 2 orders of magnitude. Thus, minor changes in the amino acid sequence of the mCLR Nterminal extracellular domain impair high affinity interactions of mCLR/mRAMP1 and mCLR/mRAMP2 heterodimers with CGRP and AM. Along these lines, the substitution of Asn 117 in a consensus N-glycosylation site of the human CLR by amino acids other than Asp abolished the CGRP and AM receptor functions in the presence of RAMP1 and RAMP2 (12) .
In conclusion, minimal amino acid deletions or substitutions in the N-terminal extracellular domain of the CLR reveal distinct CGRP and/or AM receptor defects of the respective CLR/ RAMP1 and CLR/RAMP2 heterodimers. Here, the deletion of the sequence TRNKIMT, corresponding to amino acids 14 -20 in the mCLR, selectively abolished its AM receptor function. This observation is important for the development of AM receptor deficient animals to reveal distinct biological functions of AM and CGRP in vivo.
